Supplementary Table 1. Overall AEs and SAEs by MedDRA System Organ Class by tofacitinib formulation

	Tofacitinib immediate-release			Tofacitinib extended-release		
	Number of AEs	**Number of cases with an AE (%)**	**Number of SAEs**	**Number of AEs**	**Number of cases with an AE (%)**	**Number of SAEs**
	(N = 11,184)	**(N = 3616)**	**(N = 1685)**	**(N = 228)**	**(N = 98)**	**(N = 41)**
General disorders and administration site conditions	2949	1964 (54.3)	215	59	40 (40.8)	2
Gastrointestinal disorders	1922	1063 (29.4)	584	37	20 (20.4)	19
Injury, poisoning, and procedural complications	1372	1055 (29.2)	48	58	44 (44.9)	6
Infections and infestations	818	604 (16.7)	251	16	13 (13.3)	6
Investigations	776	536 (14.8)	66	11	9 (9.2)	-
Nervous system disorders	633	512 (14.2)	65	6	6 (6.1)	1
Psychiatric disorders	477	383 (10.6)	16	8	5 (5.1)	1
Skin and subcutaneous tissue disorders	485	353 (9.8)	20	5	4 (4.1)	-
Musculoskeletal and connective tissue disorders	478	337 (9.3)	40	9	7 (7.1)	-
Respiratory, thoracic, and mediastinal disorders	450	313 (8.7)	61	8	6 (6.1)	1
Vascular disorders	154	140 (3.9)	105	3	3 (3.1)	3
Metabolism and nutrition disorders	112	108 (3.0)	11	-	-	-
Renal and urinary disorders	98	85 (2.4)	26	1	1 (1.0)	-
Blood and lymphatic system disorders	69	65 (1.8)	16	2	2 (2.0)	1
Eye disorders	78	63 (1.7)	24	1	1 (1.0)	-
Immune system disorders	64	62 (1.7)	17	-	-	-
Cardiac disorders	65	49 (1.4)	45	1	1 (1.0)	-
Neoplasms benign, malignant, and unspecified	45	41 (1.1)	39	1	1 (1.0)	1

MedDRA System Organ Classes with <1% of AEs are not shown.
AE, adverse event; MedDRA, Medical Dictionary for Regulatory Activities; N, total number of cases/events; SAE, serious adverse event.